A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)

Trial Profile

A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Acronyms PREFER
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society.
    • 22 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 01 Jul 2015 Planned End Date changed from 1 Jan 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top